Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant WomenBusiness Wire • 03/02/22
Jeff Reeves's Strength in Numbers: Haul away these 10 bargains in beaten-down quality stocks before it's too lateMarket Watch • 03/01/22
Phase 3 CLOVER Trial for Pfizer's Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary EndpointsBusiness Wire • 03/01/22
Pfizer/BioNTech vaccine found to be much less affective in preventing infection in children aged 5 to 11: NYTMarket Watch • 03/01/22
Pfizer COVID-19 vaccine may be less effective in young children ages 5-11, new data showsBusiness Insider • 03/01/22
Pfizer Covid vaccine was just 12% effective against omicron in kids 5 to 11, study findsCNBC • 02/28/22
CDC says waiting longer between Pfizer, Moderna doses may reduce rare myocarditis risk for younger menCNBC • 02/23/22
Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare ConferenceBusiness Wire • 02/22/22